中华血液学杂志
中華血液學雜誌
중화혈액학잡지
Chinese Journal of Hematology
2015年
8期
676-681
,共6页
刘莎%魏旭东%米瑞华%艾昊%尹青松%汪萍%汪小姣%范瑞华%胡杰英
劉莎%魏旭東%米瑞華%艾昊%尹青鬆%汪萍%汪小姣%範瑞華%鬍傑英
류사%위욱동%미서화%애호%윤청송%왕평%왕소교%범서화%호걸영
抗原,CD56%白血病,髓样,急性%临床特点%存活率分析
抗原,CD56%白血病,髓樣,急性%臨床特點%存活率分析
항원,CD56%백혈병,수양,급성%림상특점%존활솔분석
Antigens,CD56%Leukemia,myeloid,acute%Clinical manifestations%Survival analysis
目的 观察CD56在t(8;21)初治成人急性髓系白血病(AML)患者中的表达,探讨其与临床特征和预后的关系.方法 回顾性分析2008年1月至2014年4月收治的82例初治t(8;21)成人AML患者的临床资料,比较CD56阳性和阴性患者的临床特征及预后差异.结果 82例患者中CD56阳性者50例,阴性者32例.对两组患者的性别、年龄、血常规、有无髓外浸润、染色体核型、早期病死率、完全缓解率及3年总生存率进行比较,差异均无统计学意义(P值均＞0.05);阳性组患者CD19表达率较阴性组低(30.0％对53.1％,P=0.036),3年无病生存(DFS)率也较阴性组低(25.8％对46.9％,p=0.014),差异均有统计学意义.多因素分析结果显示CD56阳性是患者DFS的独立预后不良因素(HR=4.012,95％CI1.712～9.400,P=0.001).结论 CD56阳性合并t(8;21)初治成人AML患者预后不良.
目的 觀察CD56在t(8;21)初治成人急性髓繫白血病(AML)患者中的錶達,探討其與臨床特徵和預後的關繫.方法 迴顧性分析2008年1月至2014年4月收治的82例初治t(8;21)成人AML患者的臨床資料,比較CD56暘性和陰性患者的臨床特徵及預後差異.結果 82例患者中CD56暘性者50例,陰性者32例.對兩組患者的性彆、年齡、血常規、有無髓外浸潤、染色體覈型、早期病死率、完全緩解率及3年總生存率進行比較,差異均無統計學意義(P值均＞0.05);暘性組患者CD19錶達率較陰性組低(30.0％對53.1％,P=0.036),3年無病生存(DFS)率也較陰性組低(25.8％對46.9％,p=0.014),差異均有統計學意義.多因素分析結果顯示CD56暘性是患者DFS的獨立預後不良因素(HR=4.012,95％CI1.712～9.400,P=0.001).結論 CD56暘性閤併t(8;21)初治成人AML患者預後不良.
목적 관찰CD56재t(8;21)초치성인급성수계백혈병(AML)환자중적표체,탐토기여림상특정화예후적관계.방법 회고성분석2008년1월지2014년4월수치적82례초치t(8;21)성인AML환자적림상자료,비교CD56양성화음성환자적림상특정급예후차이.결과 82례환자중CD56양성자50례,음성자32례.대량조환자적성별、년령、혈상규、유무수외침윤、염색체핵형、조기병사솔、완전완해솔급3년총생존솔진행비교,차이균무통계학의의(P치균＞0.05);양성조환자CD19표체솔교음성조저(30.0％대53.1％,P=0.036),3년무병생존(DFS)솔야교음성조저(25.8％대46.9％,p=0.014),차이균유통계학의의.다인소분석결과현시CD56양성시환자DFS적독립예후불량인소(HR=4.012,95％CI1.712～9.400,P=0.001).결론 CD56양성합병t(8;21)초치성인AML환자예후불량.
Objective To explore the clinical features and survival of patients with CD56 expression in de-novo acute myeloid leukemia (AML)with t (8;21).Methods Clinical data of 82 de novo AML with t (8;21)who were newly diagnosed from Jan 2008 to Apr 2014 were analyzed retrospectively,50 expressed CD56 and 32 not.Clinical characteristics and prognoses were compared between patients expressing and nonexpressing CD56.Results There were no statistically significant differences in terms of age,gender,white blood cell count (WBC),percentage of bone marrow blasts,extramedullary infiltration rate,the early mortality or the presence of additional cytogenetic abnormalities between CD56+ and CD56-groups (P＞0.05).The expressions of lymphatic antigens CD19 between CD56+ and CD56-groups showed significant difference (30.0％ vs 53.1％,P=0.036).The complete remission and 3-year overall survival (OS)showed no significant differences between CD56+ and CD56-groups,while 3-year disease-free survival (DFS)showed significant differences (25.8％ vs 46.9％,P=0.014).Multivariable analysis for DFS identified CD56 positivity as an independent predictor.DFS of who received allogeneic hematopoietic stem cell transplantation (HSCT)was better than those treated with intermediate-dose cytarabine/high dose cytarabine (IDAC)as postremission therapy.Conclusion The expression of CD56 in de-novo AML with t(8;21)appeared to be associated with poorer prognosis.
